2018
DOI: 10.1111/cas.13769
|View full text |Cite
|
Sign up to set email alerts
|

Prognostic impact of the tumor immune microenvironment in synovial sarcoma

Abstract: The association between the immune status within the tumor microenvironment and prognosis in synovial sarcoma is not well understood. We aimed to investigate the tumor immune microenvironment and analyze its prognostic impact for patients with synovial sarcoma. A total of 36 primary patients who were treated in our institution were retrospectively evaluated. Infiltration of lymphocytes (CD4+, CD8+, and FOXP3+), CD163+ macrophages, and expression of human leukocyte antigen (HLA) class I and programmed death lig… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

4
46
2
1

Year Published

2019
2019
2024
2024

Publication Types

Select...
7
1
1

Relationship

1
8

Authors

Journals

citations
Cited by 54 publications
(54 citation statements)
references
References 48 publications
4
46
2
1
Order By: Relevance
“…Across all STS subtypes with ≥6 samples, the rate of PD-1 positive samples in PD-L1 expressing ones was higher than in the negative ones. These results are supported by previous studies in smaller STS cohorts or single STS subtypes demonstrating a PD-L1 and PD-1 interaction 13,14,17,21 , which collectively provide a strong rationale that PD-L1 positive patients are eligible for immune checkpoint inhibitor therapy. Furthermore, our findings support the hypothesis that cancer cells can dynamically increase PD-L1 expression to protect themselves in settings of increased numbers of TILs 12 .…”
Section: Immune Checkpoint Inhibitors Interfering With the Interactiosupporting
confidence: 81%
“…Across all STS subtypes with ≥6 samples, the rate of PD-1 positive samples in PD-L1 expressing ones was higher than in the negative ones. These results are supported by previous studies in smaller STS cohorts or single STS subtypes demonstrating a PD-L1 and PD-1 interaction 13,14,17,21 , which collectively provide a strong rationale that PD-L1 positive patients are eligible for immune checkpoint inhibitor therapy. Furthermore, our findings support the hypothesis that cancer cells can dynamically increase PD-L1 expression to protect themselves in settings of increased numbers of TILs 12 .…”
Section: Immune Checkpoint Inhibitors Interfering With the Interactiosupporting
confidence: 81%
“…SS exhibit minimal leukocyte infiltration [6, 7]. To investigate the tumor immune microenvironment in our patients, we characterized leukocyte infiltration in patient biopsies (Additional file 1: Table S1) taken prior to and following infusion by IHC staining (CD45, CD3, CD4, CD8, CD20, CD163, PD-L1, PD-1, TIM-3, and LAG-3).…”
Section: Resultsmentioning
confidence: 99%
“…PD-1/PD-L1 (programmed cell death) pathway inhibitors have shown durable clinical benefit in tumor histologies that exhibit T-cell infiltration, elevated levels of PD-L1 expression, and higher levels of nonsynonymous somatic mutation burden [5]. By comparison, SS are poorly infiltrated by T cells and have marginal PD-L1 expression [6, 7]. As in other translocation-driven tumors, SS also have a low overall mutational burden.…”
Section: Introductionmentioning
confidence: 99%
“…This contrasts with results obtained in other solid tumors 36 and a recent study reporting the poor prognosis of M2-macrophages on a small SS cohort (n = 39) based on CD163 detection by IHC. 37 This M0-macrophage signature may reflect either new monocytes recruited in tumor environment possibly via CCL2/CCR2 pathway to differentiate into M1- or M2-macrophages according to the tumor milieu or an uncommitted precursor of resident macrophages. Targeting CSF-1 receptor to restore the differentiation mechanism of M0-macrophages into dendritic cells could be an interesting therapeutic approach.…”
Section: Discussionmentioning
confidence: 99%